Health Highlights: April 3, 2009
April 4 -- Here are some of the latest health and medical news developments, compiled by editors of HealthDay:
CDC Finds Rocket Fuel Chemical in U.S. Baby Formula
A rocket fuel chemical called perchlorate was found in samples of powdered baby formula tested by U.S. Centers for Disease Control and Prevention scientists, but it's not clear how much of a health threat it poses to infants.
The largest amounts of perchlorate were found in baby formula derived from cow's milk, said the researchers, who wouldn't disclose the brands of formula they analyzed, the Associated Press reported.
Scientists have said significant amounts of perchlorate can affect the function of the thyroid, which helps set the body's metabolism. Fetal and infant brain development can be affected by thyroid problems.
But the level of risk posed by the trace amounts of perchlorate in baby formula is difficult to assess, the AP reported. Formula sold in the United States must contain iodine, which counteracts perchlorate's effects. Other factors that influence risk include the infant's size and how much formula they consume.
Potential health risks weren't examined in the CDC study, which was published last month. The Environmental Working Group issued a press release Thursday to draw public attention to the study.
-----
FDA Panel Splits on New Diabetes Drug
A U.S. Food and Drug Administration advisory panel has found that an experimental diabetes drug from Novo Nordisk does not appear to carry heart risks, but panel members were split on whether to recommend approval for the injectable medication because of its possible link to thyroid tumors.
The Danish drug maker has asked the FDA to approve liraglutide for millions of patients with type 2 diabetes. The drug has been shown to lower blood sugar levels while reducing weight, making it unique among diabetes medications.
According to the Associated Press, the panelists voted 6 to 6 on whether the drug should be approved, because research has shown it caused cancerous thyroid tumors in rats and mice. The panel voted 8 to 5 that liraglutide did not appear to hasten heart attack and other problems seen with similar drugs in recent years.
